PluraPath™
PluraPathTM is a mobile, quantitative polymerase chain reaction (qPCR)-based water-borne pathogen detection system that can provide data onsite in approximately one hour. The PluraPathTM system is designed to provide actionable data to infection control teams on up to 15 different pathogens in one test.
The PluraPathTM system fits into an overall water safety management program strategy in healthcare in the following ways:
- As a rapid, cost-effective tool – to establish the baseline of which microbial organisms are present and at what levels (using PluraPathTM Multi-strip testing for several high-consequence waterborne pathogens) either in a proactive or outbreak response mode
- As a screening tool – to identify where additional, extensive water sampling must be performed using confirmational laboratory testing with culturing and molecular techniques
- As a confirming tool – after mitigation and treatment measures have been taken
- As a routine monitoring tool – used monthly or quarterly to ensure microbial presence and level are within compliance limits (using PluraPathTM Mono-strips for single organisms or Custom-strips with only those organisms of concern in specific premises)
SequaPath™
The SequaPathTM system provides the capability to screen water for over 20,000 different bacterial genera (families), including genera of the 40+ pathogenic bacteria listed by the Centers for Disease Control & Prevention (CDC) (Opportunistic Pathogens of Premise Plumbing). The system incorporates Nephros’ proprietary filtration technology and a DNA sequencing step that makes it possible to screen rapidly for genera of waterborne pathogens. The SequaPath™ platform is portable, allowing for same-day on-site analysis.
DialyPath™
- DialyPath™ is an on-site test that identifies the presence of endotoxins in about two hours. The system was designed to deliver real-time endotoxin data to biomedical engineers in dialysis clinics and hospitals to make decisions on dialysis water systems for patient well-being, and offers potential to replace the LAL assay for the routine testing of dialysis water and dialysate. DialyPath uses qPCR technology to quantify DNA target segments in a water sample, found in all gram-negative (i.e., inflammatory) bacteria. From these results, DialyPath uses proprietary algorithms to estimate the number of endotoxin units in a water sample.